Home » Topics » BioWorld Science

BioWorld Science
RSS

Patient enrollment ongoing in phase I/II study of SOBI-003 in pediatric MPS IIIA

July 2, 2018

First-in-human study of D-0502 is enrolling participants

July 2, 2018

Ocular Therapeutix announces NDA resubmission to the FDA for Dextenza

July 2, 2018

Laboratorios del Dr. Esteve presents new pyridazine derivatives for pain

July 2, 2018

Positive CHMP opinion granted for Mepsevii for the treatment of mucopolysaccharidosis VII

July 2, 2018

Cefepime/VNRX-5133 fixed-dose combination shows promise against resistant Gram-negative bacteria

July 2, 2018

FDA lifts clinical hold for phase Ib trial of APTO-253

July 2, 2018

Epizyme patents KAT5 and KAT6A inhibitors

July 2, 2018

Vyxeos receives positive CHMP opinion

July 2, 2018

TAK-228 demonstrates potential for the treatment of NFE2L2-mutant squamous cell lung cancer

July 2, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
Researchers identify innate immune barrier against melanoma
BioWorld
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers
BioWorld Science
Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...
In the clinic for May 26, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: 858, A2 Biotherapeutics, AC Immune, Agendia, Agenus, Aktis, Ascentage,...